BioSpace News Archive

Urovant Sciences (Nasdaq: UROV) today announced the appointment of accomplished industry veteran Jim Robinson to the position of President and Chief Executive Officer.

PALATINE, Ill., March 23, 2020 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), today announced that Abuse Deterrent Pharma, LLC, its licensee of LTX-03 (Hydrocodone Bitartrate and Acetaminophen with Acura’s LIMITx™ Technology), has engaged Catalent Pharma Solutions, LLC (“Catalent”) to perform tablet manufacturing for clinical testing supplies of the product. Acura previously engaged Catalent to perform micro-particle process development for LTX-03 using hot-melt extrusion tech

Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has commenced an underwritten public offering of its common stock, Series A warrants and Series B warrants.

Axcella Health Inc. (Nasdaq: AXLA), a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health, today announced financial results for the fourth quarter and full year ended December 31, 2019 and provided a business update.

Marinus Pharmaceuticals, Inc. announced the grant of inducement awards to three new employees.

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Andrew Saik has resigned as the Company’s Chief Financial Officer (CFO) and a director of the board to pursue other professional opportunities, effective immediately.

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced an update on their business in response to the COVID-19 pandemic.

ZOLL® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, is taking aggressive steps to increase manufacturing capacity to 10,000 ventilators per month in response to the COVID-19 pandemic.

Company Benefits from Unique Chinese, Hong Kong, Macau Diagnostic Patent Rights, and Closes Deal to Help America Now